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Results: A total of 7 RCTs were identiﬁed (2,867 patients). IPD 
analyses are still pending for one trial. The pooled estimate for overall 
survival showed an improvement in favor of docetaxel whatever the 
source data used:
Trial
No. of 
pts
Design
Hazard ratio [95% CI]
Published 
data
Study report 
data
IPD
Fossella F et al. J 
Clin Oncol 2003
1218 
DC vs VC 0.85 [0.70.1.01] 0.85 [0.72;0.99] 0.89 [0.76;1.04]
DCb vs VC 0.95 [0.80;1.14] 0.95 [0.81;1.12] 1.02 [0.88;1.20]
Douillard JY et al. 
Am Oncol 2005
233 DC vs VC 0.89 [0.68;1.16] 0.89 [0.66:1.19] 0.87 [0.66;1.13]
Kubota K et al. J 
Clin Oncol 2004
311 DC vs VdC 0.73 [0.57;0.94] 0.75 [0.58;0.97] 0.71 [0.56.0.91]
Georgoulias V et al. 
J Clin Oncol 2005
413 DG vs VC 1.00 [0.80;1.26] 1.00 [0.80;1.26] 1.02 [0.81;1.27]
Pujol JL et al. Ann 
Oncol 2005
311 DG vs VC 0.90 [0.70;1.16] 0.90 [0.70;1.16]  pending
Kudoh S et al. J Clin 
Oncol 2006
180 D vs VC 0.78 [0.56;1.08] 0.78 [0.56;1.08] 0.78 [0.56;1.08]
Monnier A et al. 
Proc ASCO 2003
201 D vs V  NA (abstract) 0.95 [0.70;1.30] 0.96 [0.70;1.31]
Overall HR 0.88 [0.81;0.96] 0.89 [0.82;0.96] 0.90 [0.82;0.98]
D: docetaxel, C: cisplatin, Cb: carboplatin, G: gemcitabine, V: vinorelbine, Vd: vindesine
Conclusions: For this meta-analysis of survival, IPD conﬁrmed the 
results found with either study report data or published data. The meta-
analysis is currently on-going for other less objective endpoints such 
as tumour response and progression-free survival. Pending data will be 
available and presented at the meeting.
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Background: In the BR.21 phase III placebo-controlled study 
(Shepherd et al. NEJM 2005;353:123-132), erlotinib (Tarceva®) was 
well tolerated and signiﬁcantly improved survival, delayed symptom 
progression and improved quality of life in patients with relapsed 
advanced NSCLC. The multicentre, open-label TRUST study was initi-
ated to provide erlotinib access for patients with stage III/IV advanced 
NSCLC.
Methods: Eligible patients had failed prior chemotherapy, or were 
unsuitable for chemotherapy. Erlotinib was administered orally 150mg/
day until disease progression or unacceptable toxicity. The NCI-CTC 
v3.0 was used to grade toxicities, including: incidence and grade of 
erlotinib-related rash; serious adverse events (SAEs) and treatment-re-
lated SAEs; and adverse events (AEs) leading to treatment withdrawal. 
Other treatment-related AEs were reported if they were not included on 
a list of 15 pre-speciﬁed AEs in the study protocol (rash; pruritis; dry 
skin; diarrhoea; nausea; vomiting; stomatitis; abdominal pain; fatigue; 
dyspnoea; cough; anorexia; infection; conjunctivitis; and keratocon-
junctivitis sicca). Dose reductions (50mg increments) were allowed as 
required.
Results: 5,015 patients from 51 countries were included in the analysis 
at the data cut-off (20/11/06). Median age was 63 years (range 19–95). 
Patient characteristics: male 62%, female 38%; stage IIIB 22%, stage 
IV 78%; ECOG PS 0 21%, PS 1 53%, PS 2 20%, PS 3 6%; Caucasian 
76%, Oriental 19%, other 5%; non-smoker 28%, ever-smoker 71% 
(no data 1%); adenocarcinoma 53%, squamous-cell carcinoma 25%, 
other 21% (no data <1%); erlotinib 1st line 14%, 2nd line 48%, 3rd 
line 37%, other 1%. Data on the occurrence of rash were available for 
4,965 patients, of whom 70% experienced rash, which was mainly 
mild or moderate (among those with rash, 84% of cases were grade 
1/2 and 16% were grade 3/4). AE safety data were available for 4,423 
patients, of whom, 55% experienced at least one AE. Erlotinib-related 
SAEs were experienced by 5% of patients, the most common of these 
being gastrointestinal (GI) disorders (2% all grades, 1% ≥ grade 3). 
Lung-related SAEs occurred in <1% of patients. 10% of patients had 
at least one treatment-related AE that was not pre-speciﬁed (3% had at 
least one grade 3/4 event), but no single such event occurred in more 
than 1% of patients. Treatment discontinuation due to erlotinib-related 
AEs occurred in 6% of patients, mainly due to GI disorders (2% all 
grades, 1% ≥ grade 3) and skin disorders (2% all grades, 1% ≥ grade 
3). Lung-related AEs led to erlotinib withdrawal in <1% of patients. 
Among 4,405 patients with available data, 577 patients (13%) required 
dose reductions due to erlotinib-related events, most commonly related 
to rash (n=416) or diarrhoea (n=72). Safety results for the subgroup of 
patients who received erlotinib second-line were similar to the overall 
results. Efﬁcacy data will be presented.
Conclusions: The safety data obtained in the TRUST study of erlotinib 
in advanced NSCLC conﬁrm in a wider clinical setting the favourable 
safety proﬁle of erlotinib observed in previous clinical trials. Erlotinib 
was generally well tolerated, thus enabling the majority of patients to 
receive the full therapeutic dose.
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Background: Cetuximab (C225) is a chimerized monoclonal antibody 
that targets the epidermal growth factor receptor (EGFR). NSCLC 
commonly expresses the EGFR, which is associated with aggressive 
tumor behavior and poor clinical outcome. Preclinical model systems 
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demonstrate radiosensitization following molecular inhibition of EGFR 
signaling. 
Methods: We report a phase II trial testing the combination of C225 
with CRT in unresectable stage III NSCLC with a planned sample 
size of 84 PTS. Eligibility criteria included Zubrod performance status 
(PS) ≤ 1, weight loss ≤ 5% over past 3 months, FEV1 ≥ 1.2 l, adequate 
hematologic, hepatic, and renal function. PTS received an initial dose 
of C225 (400 mg/m2) on day 1 of week 1, then weekly doses of C225 
(250 mg/m2) until completion of therapy (weeks 2 – 17). During week 
2, PTS started CRT (63 Gy/35 fractions) with weekly carboplatin (C) 
AUC 2 and paclitaxel (P) 45 mg/m2 x 6 doses followed by C (AUC 6) 
and P (200 mg/m2) x 2 cycles (weeks 12-17). Interim monitoring for 
severe (grade ≥ 3) or excessive non-hematologic toxicities occurred 
after PTS had been treated and followed for at least 90 days after RT. 
Primary endpoints include safety and compliance of concurrent C225 
and CRT. 
Results: 93 PTS were enrolled with 87 evaluable PTS. PTS character-
istics: 57% male, median age 64 years (range 42-85), 47% PS 0, 46% 
stage IIIA. Median follow-up is 17.6 months. Response rate is 62% 
(n=54) and 18 month overall survival (OS) is 54.7%(# at risk=39). 
Adverse events related to treatment include 20%(n=17) of PTS with 
grade 4 hematologic toxicities and 7 PTS who had grade 3 esophagi-
tis. There was 1 infection related death, 1 death NOS, and 3 PTS who 
died of pulmonary complications (adult respiratory distress syndrome, 
pneumonitis, and hypoxia). 
Conclusions: The combination of C225 with CRT is feasible. Further 
study will be needed to determine whether the addition C225 to CRT 
enhances toxicity or efﬁcacy. Complete compliance and toxicity data 
along with median survival will be reported.
Session B4: Prevention & Early Detection 
 + Epidemiology 
Tuesday, September 4
B4-01 Prevention & Early Detection + Epidemiology, Tue, 13:45 - 15:30
Smoking attributable mortality in Portugal
Borges, Margarida1 Gouveia, Miguel2 Pinheiro, Luis S.1 Costa, Joao1 
Paulo, Sergio1 Vaz-Carneiro, Antonio1 
1 Lisbon Faculty of Medicine, Lisbon, Portugal 2 Portuguese Catolic 
University - School of Economics, Lisbon, Portugal 
Background: Smoking is the second major cause of death in the world. 
If current smoking patterns continue, it will cause 10 million deaths/
year by 2020. The aim of the present study is to estimate the mortality 
and DALYs (disability adjusted life years) directly related to smok-
ing in Portugal focused on the most frequent diseases associated with 
smoking, as well as the mortality and DALYs potential reduction with 
smoking cessation.
Methods: The methodology used is that of the WHO and the World 
Bank. The process involves two steps: identiﬁcation of diseases closely 
associated with smoking coded in the International Classiﬁcation of 
Diseases, and determining the quantitative relation between smok-
ing and the identiﬁed diseases using the epidemiological concepts of 
relative risk and population attributable risk. As the risk for ex-smok-
ers will never be the same as nonsmokers we determined the burden 
related to mortality if smoking ceased at present.
Results: The investigation of burden of disease from mortality at-
tributable to smoking was based on analysis of data from the National 
Statistics Institute for the year 2004. There were 6.565 DALYs lost per 
100.000. The group of diseases related to smoking is responsible for 
50% of the deaths and 39% of the DALYs. Twelve percent of the total 
disease burden due to mortality and DALYs is attributable to smoking, 
being higher for men (16% of DALYs) than for women (4%). If smok-
ing was abandoned, the burden of disease would be reduced by 53% 
(54% in men; 65% in women).
Conclusions: Twelve percent of the overall disease burden and mortal-
ity is attributable to smoking. The health gains obtained by reducing 
tobacco consumption could reach 50%. This highlights the importance 
of smoking cessation as a priority in health policies.
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Background: Occupational carcinogens occupy a special place among 
the different classes of human carcinogens. The aim of this study was 
to estimate the fraction of lung cancer incidence attributed to occupa-
tional exposures to Silica, Cadmium, Nickel, Arsenic, Chromium, Die-
sel Fumes, Beryllium, and Asbestos (the best established lung cancer 
carcinogens in the workplace).
Methods: Exposure to each of the mentioned carcinogens at national 
level was estimated using workforce data estimated by the population 
census 1995 and obtained from the ILO. The prevalence of exposure 
for each industry/ carcinogens was estimated using exposure data from 
the CAREX database (CAREX is an international information system 
on occupational exposure to known and suspected carcinogens kept and 
maintained by EU). The magnitude of relative risk of lung cancer for 
each carcinogen of interest was estimated from local and international 
literatures. The Levin modiﬁed population attributable risk (incidence) 
fraction was utilized to estimate the fraction of lung cancer incidence as 
estimated by the Tehran Population Based Cancer Registry that could 
be attributed to workplace exposure of carcinogens of interest. 
Results: The crude incidence of lung cancer was 10.4 and 5 per 
100.000 populations of male and female, respectively. Total workforce 
according to the 1995 census was 13165489 of which 12488020 were 
male and 677469 were female. Agricultural sectors with 25% hold the 
most frequent number of workforce and electrical related sector with 
0.01% hold the least frequent number of workforce. After applying the 
CAREX exposure estimate to each sector, the proportion of male work-
ers exposed to lung carcinogen was 0.08 and this ﬁgure was 0.02 for 
females. Estimating a relative risk of 1.9 for high exposure and 1.5 for 
low exposure and employing The Levin modiﬁed formula, the fraction 
of lung cancer attributed to carcinogens in the workplace among female 
was 0.015 with a 95% CI of (0.012 to 0.019) and this ﬁgures were 0.12 
with 95%CI of (0.10 to 0.15) for male. These fractions correspond to an 
estimated incidence of 1.12 cases lung cancer per 100,000 populations 
among male and 0.8 cases of lung cancer among 100,000 population of 
female. Table 3 Show Proportion of workers exposed to lung carcino-
gens, by industry based on the CAREX estimates.
